Terence Flynn, Biotech Analyst at Morgan Stanley, discusses Eli Lilly's recent stock boost and its designation as Morgan ...
Investors have shifted from thinking higher Treasury yields are an unwelcome side effect of the stronger growth promised by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback